Medication info
Telmiroget Tablets 40/20/10 mg

Telmiroget Tablets 40/20/10 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium Micronized›20.8mg / 1 tabletEzetimibe›10mg / 1 tabletTelmisartan›40mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Brown oval film-coated tablet
Packaging
30 tablets/bottle, 3 tablets/bottle, 10 tablets/PTP, 30 tablets/PTP
Approval status
Active

MFDS item code 202202207 · Approved 2022.05.24 · Insurance code 643308990

Summary

Main use
Treatment of essential hypertension, improvement of dyslipidemia, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of telmisartan and the rosuvastatin/ezetimibe combination. Take 1 tablet once daily with water, with or without food. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When telmisartan is administered concomitantly with thiazide diuretics such as hydrochlorothiazide, it provides an additional blood pressure-lowering effect. Following a dose increase, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of telmisartan is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating telmisartan treatment to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. ∘ Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed telmisartan 40 mg once daily. ○ Rosuvastatin/ezetimibe The rosuvastatin/ezetimibe combination is administered once daily, with or without food. Patients should continue a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL-cholesterol level, recommended treatment goal, and response. Primary hypercholesterolemia The dosage range of the rosuvastatin/ezetimibe combination is 5/10mg∼20/10mg once daily. The recommended initial dose is 5/10mg once daily. The dose may be adjusted in patients who require a greater reduction in LDL-cholesterol. After starting treatment with the rosuvastatin/ezetimibe combination or adjusting the dose, check blood lipid levels at intervals of 4 weeks or longer and adjust the dose accordingly; the dose may be increased to a maximum of 20/10mg once daily. Patients taking telmisartan and the rosuvastatin/ezetimibe combination concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Treatment of essential hypertension, improvement of dyslipidemia, and prevention of cardiovascular disease

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attacks
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial dyslipidemia
  • non-familial dyslipidemia
  • mixed dyslipidemia
  • elevated total cholesterol
View approved original text

This medication is used for patients who need to take Telmisartan along with Rosuvastatin/Ezetimibe simultaneously. Telmisartan helps treat essential hypertension and reduces the risk of myocardial infarction, stroke, and cardiovascular mortality in patients over 55 years of age at high risk of major cardiovascular events. It is especially suitable for patients who cannot use ACE inhibitors. Meanwhile, Rosuvastatin/Ezetimibe is used to improve blood cholesterol and lipid levels in patients with primary hypercholesterolemia and dyslipidemia. This combination lowers total cholesterol and bad cholesterol (LDL), ApoB, and triglyceride levels while increasing good cholesterol (HDL). Therefore, this medication effectively improves cardiovascular health through blood pressure and lipid management.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of telmisartan and the rosuvastatin/ezetimibe combination. Take 1 tablet once daily with water, with or without food. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When telmisartan is administered concomitantly with thiazide diuretics such as hydrochlorothiazide, it provides an additional blood pressure-lowering effect. Following a dose increase, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of telmisartan is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating telmisartan treatment to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. ∘ Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed telmisartan 40 mg once daily. ○ Rosuvastatin/ezetimibe The rosuvastatin/ezetimibe combination is administered once daily, with or without food. Patients should continue a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL-cholesterol level, recommended treatment goal, and response. Primary hypercholesterolemia The dosage range of the rosuvastatin/ezetimibe combination is 5/10mg∼20/10mg once daily. The recommended initial dose is 5/10mg once daily. The dose may be adjusted in patients who require a greater reduction in LDL-cholesterol. After starting treatment with the rosuvastatin/ezetimibe combination or adjusting the dose, check blood lipid levels at intervals of 4 weeks or longer and adjust the dose accordingly; the dose may be increased to a maximum of 20/10mg once daily. Patients taking telmisartan and the rosuvastatin/ezetimibe combination concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Precautions

This medication can cause serious harm to the fetus and newborn during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Severe muscle problems may occur, and if symptoms such as acute myalgia or myopathy arise, it is necessary to consult a physician immediately. Patients with severely impaired liver function or active liver disease should not take this medication. Patients with severely impaired kidney function should also not take this medication, and particularly, diabetic patients with compromised kidney function should avoid combination therapy. Patients with a history of muscle disease or at high risk for muscle damage should use this medication cautiously and report any muscle-related symptoms immediately to healthcare personnel. As this medication lowers blood pressure, symptoms of hypotension or dizziness may occur, so caution is needed while driving or operating machinery. This medication can increase potassium levels in the blood, so patients at risk for hyperkalemia should receive regular blood tests. Since this medication can interact with other drugs, particularly if taking antihypertensives, diuretics, anticoagulants, etc., it is essential to inform the physician. If any adverse symptoms like liver dysfunction, myalgia, severe skin rash, or breathing difficulties occur, stop the medication immediately and visit a hospital. It should be used along with a proper diet, and regular liver and kidney function tests should be performed before and during treatment. This medication contains lactose, so it should not be taken by patients with lactose intolerance. Women of childbearing age should use appropriate contraception methods to prevent pregnancy while taking this medication.

Side effects

Gastritis, gastroesophageal reflux disease, hemorrhoids, colonic polyps, vomiting, headache, increased ALT, increased AST, chest pain, facial swelling, abnormal sensation, drug intolerance, irritable bowel syndrome, esophagitis, dizziness, drowsiness, neurodegenerative disorders, positional dizziness, migraine, diabetes, glucose load impairment, depression, bronchitis, rhinitis, cystitis, onychomycosis, soft tissue infection, hepatic steatosis, liver dysfunction, liver toxicity, acute hepatitis, toxic hepatitis, increased gamma-glutamyl transferase, increased blood cholesterol, increased serum alkaline phosphatase, arrhythmia, osteoarthritis, osteoporosis, musculoskeletal stiffness, musculoskeletal discomfort, muscle weakness, sweating, dermatitis, skin burning, skin disorders, alopecia, oropharyngeal pain, nasal obstruction, respiratory distress, pelvic pain, breast cysts, drooping eyelids, diabetic retinopathy, ear discomfort, renal dysfunction, benign esophageal neoplasm, headache, facial spasms, sensory disturbances, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial swelling, rash, alopecia, conjunctivitis, tinnitus, petechiae, increased ALT, myalgia, increased CK, dizziness, constipation, increased AST, myasthenia, joint pain, fatigue, numbness, sensory disturbances, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal bloating, itching, fainting, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine, vascular edema, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, fainting, visual disturbances, dizziness, bradycardia, tachycardia, hypotension, orthostatic hypotension, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal fullness, abdominal discomfort, dry mouth, liver function abnormalities, hepatic disorders, increased sweating, itching, rash, erythema, vascular edema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, joint pain, limb pain, tendon pain, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated creatine kinase, decreased hemoglobin, palpitations, fatigue, nausea, insufficient effect, facial spasms, sensory disturbances, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial swelling, rash, alopecia, conjunctivitis, tinnitus, petechiae, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, joint pain, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, hepatic failure, memory decline, forgetfulness, amnesic syndrome, memory impairment, confusion, severe muscle weakness, ocular myasthenia, fatigue, chest pain, discomfort in the chest, edema, weakness, generalized edema, diabetic neuropathy, tremors, upper abdominal pain, vomiting, gastritis, dry mouth, epigastric discomfort, belching, gastrointestinal disturbance, gastroesophageal reflux disease, tongue disorders, palpitations, congestive heart failure, myocardial ischemia, flushing, sputum, runny nose, limb pain, joint pain, diabetes, hypoglycemia, anemia, splenomegaly, urticaria, hyperhidrosis, rash, itching, upper respiratory infection, conjunctival hyperemia, renal failure, liver function abnormalities, increased serum creatinine, hypertension, increased serum urea, increased CPK, liver function test abnormalities

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a sealed container. Storage temperature should be maintained between 1 and 30 degrees Celsius at room temperature. This will help maintain the drug's effectiveness and safety for an extended period.

Appearance and packaging

Appearance

Brown oval film-coated tablet

Package unit

30 tablets/bottle, 3 tablets/bottle, 10 tablets/PTP, 30 tablets/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.